Correction: Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway

Zhuo Y, Li S, Hu W, et al. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway *J ImmunoTher Cancer* 2022;10:e004113. doi: 10.1136/jitc-2021-004113

This article has been corrected after publication to remove Dejia Liu from the author list. This author contacted BMJ after publication to state that they should not be listed as an author on this work because they did not read the manuscript, contribute to its contents or approve the submission. The journal corresponded with the institution and other authors regarding this, and concluded that this individual should be removed from the author list as they did not fulfil BMJ's authorship criteria.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2024;**12**:e004113corr1. doi:10.1136/jitc-2021-004113corr1



BMJ